Salarius Pharmaceuticals

Salarius Pharmaceuticals is an emerging biotechnology company developing targeted therapies to treat pediatric and other cancers, including advanced solid tumors. The lead compound, Seclidemstat, represents a potential paradigm shift in cancer treatment, with our initial focus being Ewing sarcoma, a devastating bone cancer affecting children, adolescents, and young adults, for which there are currently no targeted therapies available.